Pharma AI|12 Mar 2026
Regolo's research reveals 75% of EU businesses inadvertently expose customer data to foreign surveillance.
The Story
This highlights a significant data privacy gap across European operations.
Why It Matters
For small to mid-sized pharma, CROs, or biotechs in Europe, this isn't just a compliance issue; it’s a foundational risk. Using US-based cloud AI tools without proper data residency safeguards means your sensitive data could be legally accessed by foreign governments. Your "transformation" might just be a compliance nightmare waiting for the EU AI Act to bite. I've seen this movie before, with different tech, same plot.
What To Do About It
I can audit your current data flows and AI tool usage against EU data sovereignty requirements in 1-3 days, identifying immediate risks and practical, local-first deployment options.
pharma GDPR AIclinical trial AI automationregulatory affairs AI pharmasmall pharma AICRO artificial intelligence
